Member Registration

Members of LabOps Unite: please register here.
Members of BioCT: please register here.
Members of MassBio: please register on this page. Want your organization to gain access to member rates?  Email courses@massbioed.org for more information.

Rates & Funding

Please view the discount options for courses before registering here.

Member Rate: $850
Non-Member Rate: $1,025

Deadline to apply to the WTFP Express Program: January 27, 2026.
Course ID: C-1979

Single Company Offerings

Interested in offering this training exclusively to your team?
Email courses@massbioed.org to learn more.

Description

Intro to Biotech, Business offers a practical exploration of the business considerations that shape the biotechnology industry. Participants develop a foundational understanding of how scientific innovation moves from concept to market and the factors that influence decision-making across the biotech lifecycle.

Through a mix of instruction, real-world storytelling, and small-group discussion, the course introduces key concepts such as the regulatory landscape, market dynamics, phases of development, patient populations, and safety profiles. Participants will gain a clearer picture of how business strategy, science, and regulation intersect to drive success in the life sciences.

Who should attend? This course is designed for a broad audience, including individuals who are new to the biotechnology industry—whether they are starting their careers or transitioning from another life sciences field—as well as professionals seeking a broader understanding of the business side of biotech.

For participants interested in continuing to build their business acumen, this course pairs well with Finance of Biotechnology, which offers a deeper dive into financial concepts and decision-making within the biotech industry.

Schedule

Wednesday, February 18, 2026 | 9:00–11:30 AM EST
Friday, February 20, 2026 | 9:00–11:30 AM EST
Wednesday, February 25, 2026 | 9:00–11:30 AM EST

Meet the Instructors

John Tagliamonte
SVP, Business Development, Tract Bio
John Tagliamonte has more than 30 years of experience in executive leadership with responsibility for business development, finance, commercial operations, strategic planning, and legal functions across public and private life sciences companies. As MassBio’s first Entrepreneur-in-Residence, he helped shape forward-looking program content while mentoring the next generation of biotech entrepreneurs.

Atul Deshpande, Ph.D., MBA
CEO, IMMEDIATE Therapeutics
Atul Deshpande is the Chief Executive Officer of IMMEDIATE Therapeutics, a clinical-stage biotech company dedicated to developing safe and effective therapeutic solutions to reduce heart muscle damage and prevent cardiac arrest in Acute Coronary Syndromes. Previously, he served as Chief Strategy Officer at Peptilogics and led Asia Pacific R&D strategy efforts for Sanofi in China.